Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
XOMA Corporation's quarterly P/E stands at 9.5x.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -15.79 | 9.45 | 12.46 | 107.67 | 7.89 | — | 6.38 | — | — | — | — | — | — |
| — | — | +95.3% | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 11.26 | 12.84 | 7.40 | 4.81 | 8.80 | 10.61 | 6.70 | 49.23 | 39.77 | 82.70 | 41.99 | 161.08 | 47.78 |
| — | +20.9% | +10.4% | -90.2% | -77.9% | -87.2% | -84.0% | -69.4% | -16.8% | -46.4% | -43.1% | +570.8% | +2205.5% | |
| P/B Ratio | 3.72 | 4.45 | 4.20 | 3.62 | 3.74 | 3.60 | 2.97 | 3.56 | 3.29 | 2.59 | 2.53 | 2.46 | 2.29 |
| — | +23.5% | +41.4% | +1.5% | +13.9% | +39.1% | +17.5% | +44.9% | +43.5% | +21.3% | +17.7% | +15.3% | +9.0% | |
| P/FCF | — | — | 15.21 | 34.83 | — | — | 27.25 | — | — | — | — | — | — |
| — | — | -44.2% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 7.49 | 20.35 | 12.75 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 7.49 | 8.61 | 13.93 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
XOMA Corporation's operating margin was -14.2% in Q3 2025, down 49.3 pp QoQ and up 203.1 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -32.1% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 9.4% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.3% | 90.6% | 95.0% | 91.9% | 97.7% | 100.0% | 89.5% | 99.9% | 98.6% | 97.0% | 97.6% | 87.6% | 98.1% |
| — | -9.4% | +6.1% | -8.0% | -1.0% | +3.1% | -8.3% | +13.9% | +0.5% | +3.7% | +1.8% | -10.7% | -1.8% | |
| Operating Margin | -140.3% | -14.2% | 35.1% | 37.3% | -186.5% | -217.3% | -90.9% | -470.1% | -1087.5% | -697.2% | -359.3% | -2327.2% | -417.9% |
| — | +93.5% | +138.6% | +107.9% | +82.8% | +68.8% | +74.7% | +79.8% | -160.2% | +28.1% | +25.9% | -3401.6% | -594.7% | |
| Net Margin | -48.5% | 151.3% | 70.0% | 14.9% | -45.5% | -239.6% | 144.2% | -576.8% | -1097.1% | -663.7% | -325.7% | -2245.5% | -402.2% |
| — | +163.2% | -51.4% | +102.6% | +95.8% | +63.9% | +144.3% | +74.3% | -172.8% | +28.4% | +31.4% | -2960.0% | -584.4% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.2% | 14.1% | 10.4% | 2.8% | -4.8% | -18.7% | 17.5% | -10.0% | -20.7% | -5.1% | -4.8% | -8.2% | -4.7% |
| — | +175.7% | -40.8% | +128.3% | +77.0% | -266.0% | +464.7% | -22.1% | -339.6% | -61.9% | -41.5% | -408.4% | -120.0% | |
| ROA | -6.1% | 5.8% | 4.2% | 1.1% | -1.8% | -7.4% | 6.9% | -3.8% | -11.2% | -4.4% | -4.2% | -7.2% | -4.2% |
| — | +178.7% | -39.0% | +128.8% | +84.1% | -67.5% | +265.9% | +47.1% | -169.0% | -58.6% | -39.7% | -411.5% | -120.8% | |
| ROIC | -37.6% | -0.7% | 2.9% | 4.3% | -15.1% | -16.8% | -10.4% | -8.3% | -22.6% | -5.7% | -6.0% | -11.2% | -7.9% |
| — | +95.8% | +127.5% | +151.6% | +33.0% | -192.5% | -73.8% | +25.9% | -187.0% | +8.9% | +12.6% | -264.7% | -115.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
XOMA Corporation's Debt/EBITDA ratio is 7.6x, down from 21.8x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 48.0% YoY to 3.91x, tightening the short-term liquidity position. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.46 | 1.22 | 1.24 | 1.35 | 1.46 | 1.40 | 1.22 | 1.47 | 1.40 | — | 0.00 | 0.00 | 0.00 |
| — | -12.9% | +1.6% | -8.0% | +3.7% | — | +791669.5% | +244095.5% | +511838.7% | — | -84.4% | -53.7% | -83.0% | |
| Debt / EBITDA | — | 7.58 | 21.78 | 17.67 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.15 | 3.91 | 4.88 | 5.54 | 5.15 | 7.52 | 8.71 | 9.45 | 8.68 | 3.34 | 5.42 | 4.47 | 8.98 |
| — | -48.0% | -44.0% | -41.4% | -40.7% | +125.4% | +60.7% | +111.7% | -3.3% | -77.3% | -47.7% | -60.7% | +20.1% | |
| Quick Ratio | 5.15 | 3.91 | 4.88 | 5.54 | 5.15 | 7.52 | 8.71 | 9.45 | 8.68 | 3.34 | 5.42 | 4.47 | 8.98 |
| — | -48.0% | -44.0% | -41.4% | -40.7% | +125.4% | +60.7% | +111.7% | -3.3% | -77.3% | -47.7% | -60.7% | +20.1% | |
| Interest Coverage | -2.89 | -0.40 | 1.42 | 1.71 | -4.79 | -4.48 | -2.96 | -1.97 | -35.03 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonXOMA Corporation's current P/E is -15.8x. The average P/E over the last 4 quarters is 34.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
XOMA Corporation's current operating margin is -140.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking XOMA Corporation's business trajectory between earnings reports.